Psilocybin therapy

What psilocybin is

Psilocybin is a naturally occurring tryptamine produced by a family of fungi most often called "psilocybin mushrooms" or "magic mushrooms." The best-studied species is Psilocybe cubensis, though around 200 species synthesize psilocybin or its close analogs. The molecule was first isolated and named by Albert Hofmann of Sandoz in 1958 — the same chemist who had synthesized LSD 20 years earlier.¹

Psilocybin itself is a prodrug. Within ~15–30 minutes of ingestion the body dephosphorylates it into psilocin, a potent partial agonist at the 5-HT_2A serotonin receptor. This is the mechanism shared with LSD, DMT, and ayahuasca, and the reason these four are grouped as "classic psychedelics" — pharmacologically distinct from ketamine (which acts on NMDA glutamate receptors) and MDMA (which releases serotonin rather than binding the receptor).

How psilocybin therapy works

The clinical trial protocol

The protocol most psilocybin-for-depression trials use looks roughly the same across research groups (Johns Hopkins, NYU, Imperial College London, Usona Institute, COMPASS Pathways):

• Two to three preparation sessions with a therapist or facilitator, often 8–12 hours total.
• One dosing session of 25 mg of synthetic psilocybin (approximately equivalent to 5 grams of dried mushrooms), taken orally, lasting 4–6 hours. The participant lies on a couch, wears eye shades, listens to a specific music playlist, and is accompanied by two trained facilitators for the duration.
• One or more integration sessions within 24–72 hours of the dose, plus follow-up.

The dose itself is only a small fraction of the total therapist contact time. This — not the pharmacology alone — is the part many clinicians think drives outcomes.

Oregon Measure 109 (regulated, legal, not medical)

Oregon voters approved Measure 109 in November 2020, and in January 2023 the state began licensing "psilocybin service centers." Participants over 21 can access psilocybin services at a licensed center without a prescription or diagnosis. It is not practicing medicine — Oregon explicitly positions it as non-medical supported use — and is not covered by insurance. Costs typically run $1,800–$3,000 per session depending on facilitator and center.

Colorado Prop 122 (emerging framework)

Colorado voters approved Proposition 122 in 2022, legalizing adult personal use of psilocybin and related tryptamines and establishing a state-licensed "healing centers" framework that began issuing licenses in 2025. Prop 122 is broader than Oregon's law in scope (covers psilocin, ibogaine, mescaline, and DMT) but similar in structure (licensed facilitator, designated location, no medical claims).

FDA Breakthrough Therapy pipeline

Psilocybin holds FDA Breakthrough Therapy designation for both treatment-resistant depression (COMPASS Pathways) and major depressive disorder (Usona Institute). Breakthrough designation accelerates FDA review but does not approve the drug. As of 2026, Phase 3 trials are ongoing; there is no FDA-approved psilocybin product.

What the evidence actually supports

Treatment-resistant depression

COMPASS Pathways' Phase 2b trial (n=233, published in the New England Journal of Medicine in 2022) compared three doses (25 mg, 10 mg, 1 mg). The 25 mg arm produced a larger drop in depression scores at week 3 versus the 1 mg "active-placebo" control.² At 12 weeks the between-group difference narrowed. This is the largest psilocybin-for-depression trial published to date.

Major depressive disorder (not treatment-resistant)

A 2022 JAMA trial (n=104) compared 25 mg psilocybin to niacin placebo across 8 weeks of follow-up; the psilocybin arm showed a significantly larger reduction in depression severity at 6 weeks.³

Existential distress in cancer patients

Two well-known 2016 trials (Johns Hopkins and NYU, both published in Journal of Psychopharmacology) showed substantial reductions in anxiety and depression among patients with life-threatening cancer, with benefits persisting at 6-month follow-up in subsets.⁴ These trials are small but the effect sizes are among the largest reported for any psychiatric intervention.

The blinding problem (a caveat)

Safety & side effects

Psilocybin has a favorable physiological safety profile compared to ketamine or MDMA. It is not physically dependence-forming. It does not produce the cystitis concern of chronic ketamine or the serotonergic concerns of high-dose MDMA. The main safety concerns are psychological and acute:

• Acute anxiety / "bad trips" — transient but intense. The preparation and facilitator relationship are the primary mitigations.
• Prolonged perceptual effects (HPPD) — rare but documented; risk appears higher in people with prior exposure to multiple psychedelics.
• Psychosis risk — a theoretical concern for people with a personal or family history of schizophrenia or bipolar I. Every rigorous trial excludes these populations, so we cannot speak to their safety profile from published data.
• Cardiovascular: psilocybin raises heart rate and blood pressure modestly; relevant for patients with uncontrolled cardiovascular disease.

Drug interactions. Psilocybin's effects are reduced or blocked by SSRIs/SNRIs because both act on 5-HT_2A. Any facilitator worth their license will ask about your current antidepressant regimen, and most will require a taper schedule before a session.

Legal status in the US

Psilocybin is a Schedule I controlled substance federally, defined as having no accepted medical use. The two exceptions to date are state regulated adult-use programs in Oregon (Measure 109, operational since 2023) and Colorado (Prop 122, operational 2025). These programs operate in tension with federal law — the DEA has not enforced against licensed state-legal operations, but the federal Schedule I designation remains unchanged. See our legal status by state tool for the current state-by-state map.

How to access it (honestly)

If you are US-based, three paths exist today:

1. Oregon or Colorado licensed centers. Legal, regulated, non-medical. Most straightforward way to participate in an adult-use session with trained facilitators. Expect to pay $1,800–$3,000 out of pocket.
2. Clinical trials. Phase 2 and Phase 3 trials at institutional sponsors (COMPASS, Usona, university medical centers) recruit continuously. ClinicalTrials.gov lists open sites; you'll need to meet diagnostic criteria.
3. International retreats. Jamaica, the Netherlands (where psilocybin-containing truffles remain legal), and a few other jurisdictions host licensed retreat programs. See the retreat finder.

What this guide does not endorse is unregulated purchase of mushrooms or therapy from any provider who cannot tell you their license number, state of operation, and integration protocol.

Preparation & integration

As with ketamine, outcomes correlate more tightly with the quality of preparation and the post-session integration relationship than with the specifics of the dosing protocol. See the integration therapy guide for what this should look like.